HPLC, UHPLC
HLPC used in tobramycin study
Oct 20 2011
In a study published by Critical Care, a team from the Netherlands noted that tobramycin is one of the components used for selective decontamination of the digestive tract (SDD), applied to prevent colonisation and subsequent infections in critically ill patients.
Tobramycin is not normally absorbed into the body but the team hypothesised that the critical illness may cause a failure of the gut barrier, causing the components to be absorbed.
Using high performance liquid chromatography - mass spectrometry/mass spectrometry (HLPC-MS/MS), the scientists tested the blood and urine of 71 patients, once daily for seven days.
The team found that 99 per cent of those studied had at least one positive urine sample and 49 per cent had a urinary concentration greater than or equal to 1 mg/L.
"The majority of acute critically ill patients treated with enteral tobramycin as a component of SDD had traces of tobramycin in blood, especially those with severe shock, inflammation and subsequent acute kidney injury," the team concluded.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Sep 04 2024 Chiba, Tokyo, Japan